Current Allergy and Asthma Reports

, Volume 6, Issue 6, pp 445–447

Atopic Eczema

Invited Commentary

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ring J: Allergy in Practice. Heidelberg: Springer, 2005.Google Scholar
  2. 2.
    Friedmann PS, Holden CA: Atopic dermatitis. In Rook’s Textbook of Dermatology, edn 7. Edited by Burns T,Breathnach S, Cox N, Griffiths C. Oxford: Blackwell, 2006.Google Scholar
  3. 3.
    Ring J, Krämer U, Schäfer T, Behrendt H: Why are allergies increasing? Curr Opinion Immunol 2001, 13:701–708.CrossRefGoogle Scholar
  4. 4.
    Wüthrich B: Epidemiology and natural history of atopic dermatitis. Allergy Clin Immunol Int 1996, 8:77–82.Google Scholar
  5. 5.
    Schultz-Larsen F: Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1993, 28:719–723.PubMedCrossRefGoogle Scholar
  6. 6.
    Cookson WO, Moffatt MF: The genetics of atopic dermatitis. Curr Opin Allergy Immunol 2002, 2:383–387.CrossRefGoogle Scholar
  7. 7.
    Leung DYM, Jain N, Leo HL: New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol 2003, 15:634–638.PubMedCrossRefGoogle Scholar
  8. 8.
    Tamura K, Suzuki M, Arakawa H, et al.: Linkage and association studies of STAT6 gene polymorphisms and allergic diseases. Int Arch Allergy Immunol 2003, 131:33–38.PubMedCrossRefGoogle Scholar
  9. 9.
    Novak N, Kruse S, Kraft S, et al.: Dichotomic nature of atopic dermatitis reflected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the interleukin-4/interleukin-13 receptor gene: the dichotomy of extrinsic and intrinsic atopic dermatitis. J Invest Dermatol 2002, 119:870–875.PubMedCrossRefGoogle Scholar
  10. 10.
    Arkwright PD, Chase JM, Babbage S, et al.: Atopic dermatitis is associated with a low-producer transforming growth factor beta(1) cytokine genotype. J Allergy Clin Immunol 2001, 108:281–284.PubMedCrossRefGoogle Scholar
  11. 11.
    Yagi R, Nagai H, Iigo Y, et al.: Development of atopic dermatitis-skin lesions in STAT6-deficient NC/Nga mice. J Immunol 2002, 168:2020–2027.PubMedGoogle Scholar
  12. 12.
    Sandford AJ, Shirakawa T, Moffatt MF, et al.: Localisation of atopy and beta subunit of high-affinity IgE receptor (Fc epsilon RI) on chromosome 11q. Lancet 1993, 341:332–334.PubMedCrossRefGoogle Scholar
  13. 13.
    Weidinger S, Klopp N, Wagenpfeil S, et al.: Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. J Med Genet 2004, 41:658–663.PubMedCrossRefGoogle Scholar
  14. 14.
    Wiliams HC: Atopic dermatitis. N Engl J Med 2005, 352:2314–2324.CrossRefGoogle Scholar
  15. 15.
    Sampson HA, Albergo R: Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis. J Allergy Clin Immunol 1984, 74:26–33.PubMedCrossRefGoogle Scholar
  16. 16.
    Darsow U, Laifaoui J, Kerschenloh K, et al.: The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy 2004, 59:1318–1325.PubMedCrossRefGoogle Scholar
  17. 17.
    Darsow U, Ring J: Airborne and dietary allergens in atopic eczema: a comprehensive review of diagnostic tests. Clin Exp Dermatol 2000, 25:544–551.PubMedCrossRefGoogle Scholar
  18. 18.
    Möhrenschlager M, Schäfer T, Huss-Marp J, et al.: The course of eczema in children aged 5–7 years and its relation to atopy: differences between boys and girls. Br J Dermatol 2006, 154:505–513.PubMedCrossRefGoogle Scholar
  19. 19.
    Abeck D, Burgdorf W, Cremer H: Common Skin Diseasesin Children. Darmstadt: Steinkopff, 2003.Google Scholar
  20. 20.
    Wollenberg A, Sharma S, von Bubnoff D, et al.: Topical tacrolimus (FK 506) leads to profound phenotypic alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001, 107:519–525.PubMedCrossRefGoogle Scholar
  21. 21.
    Panhans-Gross A, Novak N, Kraft S, Bieber T: Human epidermal Langerhans’ cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001, 107:345–352.PubMedCrossRefGoogle Scholar
  22. 22.
    Zuberbier T, Chong SU, Grunow K, et al.: The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001, 108:275–280.PubMedCrossRefGoogle Scholar
  23. 23.
    Reitamo S, Van Leent EJ, Ho V, et al.: Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002, 109:539–546.PubMedCrossRefGoogle Scholar
  24. 24.
    Reitamo S, Harper J, Bos JD, et al.: 0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized doubleblind controlled trial. Br J Dermatol 2004, 150:554–562.PubMedCrossRefGoogle Scholar
  25. 25.
    Eichenfleld LF, Lucky AW, Boguniewicz M, et al.: Safety and Efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002, 46:495–504.CrossRefGoogle Scholar
  26. 26.
    Center for Drug Evaluation and Research: Alert for healthcare professionals: pimecrolimus (marketed as Elidel). Rockville, MD: Food and Drug Administration; March 2005.Google Scholar
  27. 27.
    Center for Drug Evaluation and Research: Alert for healthcare professionals: taccrolimus (marketed as Protopic). Rockville, MD: Food and Drug Administration; March 2005.Google Scholar
  28. 28.
    Food and Drug Administration Pediatric Advisory Committee: February 15, 2005, Briefing Information. http://www.fda.gov/ohrms/dockets/ac/05/Briefing/2005-4089b2.htm. Accessed August 4, 2006.Google Scholar
  29. 29.
    Allen BR, Lakhanpaul M, Morris A, et al.: Systemic exposure, tolerability and Efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003, 88:969–973.PubMedCrossRefGoogle Scholar
  30. 30.
    Bieber T, Cork M, Ellis C, et al.: Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005, 211:77–78.PubMedCrossRefGoogle Scholar
  31. 31.
    Mallon E, Powell S, Bridgman A: Wet-wrap dressings for the treatment of atopic eczema in the community. J Dermatol Treat 1994, 5:97–98.Google Scholar
  32. 32.
    Keane FM, Munn SE, du Vivier AWP, et al.: Analysis of Chinese herbal creams prescribed for dermatological conditions. BMJ 1999, 318:563–564.PubMedGoogle Scholar
  33. 33.
    McMenamy CJ, Katz RC, Gipson M: Treatment of eczema by EMG biofeedback and relaxation training: a multiple baseline analysis. J Behav Ther Exp Psychiatry 1988, 19:221–227.PubMedCrossRefGoogle Scholar
  34. 34.
    Schachner L, Field T, Hernandez-Reif M, et al.: Atopic dermatitis symptoms decreased in children following massage therapy. Ped Dermatol 1998, 15:390–395.CrossRefGoogle Scholar
  35. 35.
    Senser C, Habermüller M, Revenstorf D: Hypnotherapie bei atopischer Dermatitis. Akt Dermatol 2004, 30:103–108.CrossRefGoogle Scholar
  36. 36.
    Staab D, Diepgen TL, Fartasch M, et al.: Age-related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006, 332:933–938.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Division of Environmental Dermatology and Allergy GSF/TUM, Department of Dermatology and Allergy BiedersteinTechnical University of MunichMunichGermany

Personalised recommendations